Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.
Framatome to produce Lu-177 at Romania’s Cernavoda
Framatome and SN Nuclearelectrica, a partially state-owned Romanian nuclear energy company, have entered into a long-term cooperation agreement to produce the medical isotope lutetium-177 at...
Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares
Oklo Inc. has that it has signed a letter of intent to acquire Atomic Alchemy Inc., a U.S.-based radioisotope production company. The two companies announced a strategic partnership earlier...
TerraPower reaches market-scale production of Ac-225
TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the...
Australia’s OPAL is back at work after upgrades
The only nuclear reactor in Australia has returned to power after a monthslong shutdown for planned essential maintenance and upgrades. The OPAL (for open-pool Australian light water reactor)...
QSA Global, Niowave to collaborate on Ac-225 production using Ra-226
QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification...
Decay on Demand: DARPA’s bid to disrupt isotope production
The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) wants to mimic and accelerate the natural half-life decay chain of alpha-emitting radioisotopes and plans to...
ANS Annual Conference special plenary: Our friends the isotopes
“What can the atom do for you, other than produce electricity from nuclear reactors?” That was the question asked and answered during an ANS Annual Conference special plenary session on...
Orano Med inaugurates Pb-212 production facility in Indiana
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near...
Zeno looks to SHINE for Sr-90 to fuel its radioisotope power systems
Wisconsin-based fusion technology company SHINE Technologies announced today the signing of a memorandum of understanding with Zeno Power to develop a nuclear materials supply chain for its...
Oklo’s Diané presents at Community of Practice
The American Nuclear Society’s Risk-informed, Performance-based Principles and Policy Committee (RP3C) held another Community of Practice (CoP) on April 26. For this event, the committee...